Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionIWM - iShares Russell 2000 ETF
Latest Disclosed Ownership2,836,036 shares
Latest Disclosed Value $ 70,220,251
IWM - iShares Russell 2000 ETF reports 2.99% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On May 28, 2026 - IWM - iShares Russell 2000 ETF filed a NPORT-P form disclosing ownership of 2,836,036 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $70,220,251 USD as of March 31, 2026. The entity filed a previous NPORT-P on February 25, 2026 disclosing 2,923,328 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -2.99% during the quarter. The current value of the position is $89,306,774 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-28 2026-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,836,036 -87,292 -2.99 70,220 2.92 0.0976
2026-02-25 2025-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,923,328 42,328 1.47 68,230 20.22 0.0925
2025-11-26 2025-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,881,000 5,164 0.18 56,756 -9.05 0.0800
2025-08-28 2025-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,875,836 -120,792 -4.03 62,406 -14.12 0.0986
2025-05-27 2025-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,996,628 5,415 0.18 72,668 16.41 0.1137
2025-02-27 2024-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,991,213 91,497 3.16 62,427 8.29 0.0865
2024-11-26 2024-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,899,716 300,154 11.55 57,646 43.16 0.0829
2024-08-27 2024-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,599,562 -117,172 -4.31 40,267 -7.01 0.0671
2024-05-28 2024-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,716,734 70,095 2.65 43,305 -2.67 0.0661
2024-02-27 2023-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,646,639 324,228 13.96 44,490 63.88 0.0660
2023-11-22 2023-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,322,411 139,165 6.37 27,149 -7.48 0.0521
2023-08-25 2023-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,183,246 90,284 4.31 29,343 -15.44 0.0538
2023-05-26 2023-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,092,962 -131,254 -5.90 34,701 -16.12 0.0690
2023-02-24 2022-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,224,216 171,394 8.35 41,370 57.08 0.0788
2022-11-28 2022-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,052,822 -225,108 -9.88 26,338 64.94 0.0554
2022-08-25 2022-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,277,930 88,146 4.03 15,968 -12.04 0.0310
2022-05-26 2022-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,189,784 -56,834 -2.53 18,153 19.36 0.0292
2022-02-25 2021-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,246,618 72,964 3.36 15,210 32.02 0.0220
2021-11-24 2021-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,173,654 -129,667 -5.63 11,520 -13.02 0.0173
2021-08-26 2021-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,303,321 -59,503 -2.52 13,244 21.59 0.0190
2021-05-27 2021-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,362,824 98,919 4.37 10,893 44.06 0.0158
2021-02-25 2020-12-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,263,905 305,853 15.62 7,561 30.03 0.0129
2020-11-25 2020-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 1,958,052 -94,471 -4.60 5,815 -38.67 0.0150
2020-08-27 2020-06-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,052,523 -171,489 -7.71 9,483 10.75 0.0258
2020-06-01 2020-03-31 NP Catalyst Pharmaceuticals EC US14888U1016 2,224,012 -13,510 -0.60 8,562 2.05 0.0259
2020-02-27 2019-12-31 NP Catalyst Pharmaceuticals EC 14888U101 2,237,522 14,668 0.66 8,391 -28.92 0.0174
2019-11-25 2019-09-30 NP Catalyst Pharmaceuticals EC US14888U1016 2,222,854 2,222,854 11,803 0.0271
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.